Theravance Biopharma, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$22.3M
Doctors Paid
2,890
Transactions
12,602
2018 Total
$5.8M
Payment Breakdown by Category
Research$20.1M (90.3%)
Consulting$1.1M (5.1%)
Travel$271,245 (1.2%)
Food & Beverage$261,332 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $20.1M | 2,406 | 90.3% |
| Consulting Fee | $1.1M | 399 | 5.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $474,443 | 247 | 2.1% |
| Travel and Lodging | $271,245 | 568 | 1.2% |
| Food and Beverage | $261,332 | 8,637 | 1.2% |
| Space rental or facility fees (teaching hospital only) | $23,450 | 19 | 0.1% |
| Education | $1,982 | 326 | 0.0% |
Payments by Type
Research
$20.1M
2,405 transactions
General
$2.2M
10,196 transactions
Ownership
$0
1 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| 0128 TD-4208 | $4.3M | 6 | 931 |
| 0149_PIFR | $1.5M | 1 | 248 |
| Protocol #0112 | $1.5M | 1 | 175 |
| TD-5108 | $1.2M | 0 | 146 |
| 0126 TD-4208 | $1.2M | 1 | 92 |
| TOUR 1-7X84ZY | $1.2M | 2 | 141 |
| PRIZM.1439.PH1 | $1.2M | 0 | 14 |
| 99 | $981,137 | 1 | 207 |
| 0127 TD-4208 | $891,772 | 0 | 76 |
| 28-day Parallel Group Safety Study of Revefenacin in COPD | $887,599 | 1 | 37 |
| 145 | $748,947 | 0 | 3 |
| 152 | $708,443 | 0 | 5 |
| IRB 160586 | $467,830 | 0 | 3 |
| Phase 3 Randomized Double-Blind Double-Dummy Parallel-Group Study to Compare Once Daily Nebulized Revefenacin with Spiriva | $416,758 | 1 | 69 |
| TBPH0144 | $412,853 | 1 | 40 |
| Phase 2 TD-9855 Neurogenic Orthostatic Hypotension | $387,858 | 0 | 5 |
| Study VUMC57544 | $306,358 | 0 | 1 |
| 0120 TOUR | $167,464 | 2 | 35 |
| Phase 3b 28-day Randomized Active Controlled Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized Revefenancin | $154,628 | 1 | 23 |
| Protocol 0174 | $148,409 | 0 | 1 |
| A Study of the Mechanism of Televancin Resistance | $146,756 | 0 | 2 |
| Phase 1, Fixed-Sequence, Open-label Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine, Cigarette Smokign and Itraconazole on the Pharmacokinetics of TD-9855 | $92,560 | 0 | 1 |
| Treatment of COPD | $85,273 | 0 | 8 |
| PRIZM.0714.PH1 | $76,995 | 0 | 3 |
| Study 126523 Pharmacokinetics and Tolerability of TLVN | $75,757 | 0 | 1 |
| Phase 3b, 28-day, Randomized, Active-Controlled, Parallel Group Study to Evaluate Safety and Tolerability of Nebulized Revefenacin adminstersed before Nebulized Formoterol Fumarate | $75,018 | 1 | 15 |
| TD-9855 0145 | $74,440 | 0 | 1 |
| MARIN.9855.PH2 | $68,902 | 0 | 3 |
| Pharmacokinetics and Tolerability of Telavancin in Cystic Fibrosis | $55,757 | 0 | 1 |
| Phase 2 Efficacy study in subjects with Crohn's Disease | $35,410 | 0 | 5 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2018 |
|---|---|---|---|---|
| Dr. Kenneth Colley, Md, MD | Internal Medicine | San Francisco, CA | $336,074 | $0 |
| Dr. Hugh Windom, M.d, M.D | Allergy | Sarasota, FL | $256,522 | $0 |
| Dr. Shahrukh Kureishy, Md, MD | Pulmonary Disease | Mckinney, TX | $117,234 | $0 |
| Charles Sims, Md, MD | Infectious Disease | Shenandoah, TX | $85,255 | $0 |
| Dr. Ali Hassoun, Md, MD | Infectious Disease | Huntsville, AL | $77,998 | $0 |
| Dr. Tim Shepherd, M.d, M.D | Family Medicine | Lewisville, TX | $60,735 | $0 |
| Adnan Siddiqui, Md, MD | Specialist | Bridgeton, MO | $56,650 | $0 |
| Dr. Micah Jacobs, Md, MD | Infectious Disease | Pittsburgh, PA | $55,827 | $0 |
| Dino Delaportas, M.d, M.D | Infectious Disease | Bridgeport, WV | $51,018 | $0 |
| Edward Mccluskey, Md, MD | Anesthesiology | Loma Linda, CA | $46,390 | $0 |
| Terry Wells, Md, MD | Family Medicine | Lufkin, TX | $38,477 | $0 |
| Bruce Friedman, M.d, M.D | Critical Care Medicine | Augusta, GA | $37,728 | $0 |
| Dr. Robert Garver, Md, MD | Pulmonary Disease | Andalusia, AL | $34,151 | $0 |
| Dr. Javeed Siddiqui, Md, Mph, MD, MPH | Infectious Disease | Roseville, CA | $29,059 | $0 |
| Dr. Laurie Smaldone Alsup | Medical Oncology | Pennington, NJ | $27,457 | $0 |
| Dr. Marianne Mann, Md, MD | Internal Medicine | Highland, MD | $26,125 | $0 |
| Dr. Susan Jerian, M.d, M.D | Internal Medicine | Westlake Village, CA | $24,873 | $0 |
| Dr. Alexander Evens, D.o, D.O | Infectious Disease | Turlock, CA | $24,856 | $0 |
| Sara Cosgrove, M.d, M.D | Infectious Disease | Baltimore, MD | $23,310 | $0 |
| Dr. Paras Udani, Do, DO | Infectious Disease | Pomona, NJ | $22,369 | $0 |
| Dr. Steven Burdette, Md, MD | Infectious Disease | Dayton, OH | $21,733 | $0 |
| Vivian Chu, Md, MD | Infectious Disease | Durham, NC | $20,550 | $0 |
| Unknown Provider | — | — | $20,084 | $0 |
| Chris Farnum, Do, DO | Internal Medicine | Lansing, MI | $19,580 | $0 |
| Dr. Juan Diaz, D.o, D.O | Infectious Disease | Altamonte Springs, FL | $18,729 | $0 |
About Theravance Biopharma, Inc.
Theravance Biopharma, Inc. has made $22.3M in payments to 2,890 healthcare providers, recorded across 12,602 transactions in the CMS Open Payments database. In 2018, the company paid $5.8M. The top product by payment volume is VIBATIV ($2.6M).
Payments were distributed across 85 medical specialties. The top specialty by payment amount is Infectious Disease ($836,991 to 846 doctors).
Payment categories include: Food & Beverage ($261,332), Consulting ($1.1M), Research ($20.1M), Travel & Lodging ($271,245).
Theravance Biopharma, Inc. is associated with 1 products in the CMS Open Payments database.